H.C. Wainwright lowered the firm’s price target on Verve Therapeutics (VERV) to $14 from $15 and keeps a Buy rating on the shares after the company announced that it has dosed seven patients with its second-generation PCSK9 base editor, VERVE-102, in the Phase 1b trial in adults living with heterozygous familial hypercholesterolemia. The next major catalyst should be VERVE-102 data in the first half of 2025, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on VERV:
- Verve Therapeutics Reports Q3 Progress and Financials
- Verve Therapeutics reports Q3 EPS (59c), consensus (70c)
- Verve Therapeutics sees cash runway through 2026
- Verve Therapeutics, Inc. (VERV) Q3 Earnings Cheat Sheet
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
%20Q2%20Earnings%20Top%20Estimates%2C%202024%20EPS%20View%20Down%20%7C%20Nasdaq&_biz_n=1&rnd=850784&cdn_o=a&_biz_z=1743680248652)
